Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00895102 · ClinicalTrials.gov registry record · Phase 1
Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00895102 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 34 participants.
The verdict
NCT00895102, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the bioavailability, pharmacokinetic and safety profiles of an experimental Hepatitis C virus (HCV) polymerase inhibitor in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG ABT-333 Tablet
- DRUG ABT-333 Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00895102
The ClinicalTrials.gov registry entry for NCT00895102 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00895102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00895102 about?
NCT00895102 is a clinical study titled "Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers". The purpose of this study is to determine the bioavailability, pharmacokinetic and safety profiles of an experimental Hepatitis C virus (HCV) polymerase inhibitor in healthy volunteers.
What is the current status of trial NCT00895102?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2009-04.
What interventions are being tested in trial NCT00895102?
The interventions under investigation include: Placebo (DRUG), ABT-333 Tablet (DRUG), ABT-333 Capsule (DRUG).
Who is sponsoring clinical trial NCT00895102?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.